Genes for ovalbumin-luteinizing hormone-releasing hormone 7 (LHRH-7) and thioredoxin-LHRH-7 fusion proteins (containing seven LHRH inserts) were constructed by cassette and mismatch mutagenesis and expressed in Escherichia coli. In experiment 1, 10 g of either ovalbumin-LHRH-7 or thioredoxin-LHRH-7 were suspended in Z-max adjuvant and injected three times at 4-wk intervals into postpubertal male BALB/c mice. In experiment 2, the fusion proteins were suspended in Immumax adjuvant and administered in equimolar quantities (0.4 nmol per injection) to postpubertal male BALB/c mice. In addition to injection of these two proteins alone, the proteins were also administered in different sequences or together in a mixture. Both LHRH fusion proteins induced significant antibody titers, which resulted in a significant decrease in vesicular gland and anterior prostate weight (measure of biological response) in both experiments. Vesicular gland and anterior prostate weight and LHRH antibody titers were significantly correlated in experiments 1 (r ‫؍‬ Ϫ0.64) and 2 (r ‫؍‬ Ϫ0.53). Percentage of animals responding to treatment varied from 40-60% in experiment 1 and from 11-89% in experiment 2, with the highest responses in treatments that used a combination of both fusion proteins. The variation in responders and nonresponders was evaluated by estimating antibody K D from displacement curves. Part, but not all, of the high antibody nonresponders can be explained by antibody affinity.
INTRODUCTION
It was first reported in 1973 that male rabbits immunized against luteinizing hormone-releasing hormone (LHRH) for development of a radioimmunoassay had decreased gonadal size [1] . Since that time, other researchers have shown that LHRH vaccines suppress concentrations of LH and testosterone in peripheral circulation and cause atrophy of the testes in numerous species [2] [3] [4] [5] . Because the prostate is an androgen-dependent organ, LHRH immunization also results in atrophy of the prostate and other accessory sex glands in rats and bonnet monkeys [3, 6, 7] .
Over 55 years ago, it was originally observed that orchidectomy could cause sustained remission of prostatic cancer by virtually eliminating testosterone production [8] . In drastic cases, orchidectomy is still performed in an attempt to control prostate cancer. In humans, immunoneutralization of LHRH using an LHRH vaccine could be valu- able for treating severe cases of androgen-dependent prostate carcinoma by lowering testosterone concentrations and inducing atrophy of the prostate.
One major requirement that exists before LHRH vaccines can be used commercially in the United States is that they must have a uniform molecular structure within and between batches to gain Food and Drug Administration (FDA) approval. Most LHRH vaccines developed to date do not meet this requirement because the carrier protein is conjugated to LHRH by a chemical process that does not insure the production of immunogens with a homogenous structure.
The objective of this study was to evaluate two genetically engineered LHRH fusion proteins that have the potential to be approved by the FDA. The construction and purification of ovalbumin-LHRH-7 has been described previously [9] and its effects examined in female mice and cattle [9, 10] . Thioredxoin-LHRH-7 is presented for the first time in this paper. Both fusion proteins were administered alone and in combination to determine their ability to induce LHRH antibody titers capable of decreasing the size of testes and accessory sex glands in male mice.
MATERIALS AND METHODS

Development and Purification of Ovalbumin-LHRH-7
Ovalbumin-LHRH-7 ( Fig. 1) was produced using the protocol described previously [9] . Escherichia coli strains BL21(DE3) (Novagen Inc., Madison, WI) and MV1190 were used for cloning and expressing ovalbumin-LHRH genes. Ovalbumin-LHRH-7 was obtained after sonication of the bacterial cells, followed by centrifugation and SDS-PAGE analysis of the pellet and supernatant fractions. Proteins were first solubilized in 6 M urea, centrifuged, filtered through a 0.45 m membrane, and then purified by Hisbind affinity chromatography [11] .
Construction of Recombinant Plasmid pET-Thioredoxin-LHRH-7 pET32b (Novagen) was used as a parental plasmid expressing the thioredoxin protein under the control of phage T7 promoter. To insert the LHRH dimer sequence in the active-site loop (Cys32-Gly-Pro-Cys35) of thioredoxin, two complementary synthetic oligonucleotides, LHRH-a and LHRH-b (75 nucleotides of each; Table 1 ) were annealed to generate a short duplex. The LHRH dimer sequence was flanked by Gly-Gly linkers in the duplex. This duplex with Rsr II sticky ends was then ligated into the Rsr II site in pET32b. The Rsr II site was located at the active-site loop of thioredoxin [12] . The resulting plasmid was designated pET-thioredoxin-LHRH-2AS.
A 66-base pair (bp) HindIII-XhoI fragment that encoded for the other LHRH dimer sequence was isolated from pET24b-OVA-LHRH-7 and then inserted into the HindIII- -GTC CAG GTG GTC AGC ATT GGT CTT ACG GTC TGC GCC CAG GCC AAC ACT GGA GCT ATG GCC TCC  GTC CGG GTG GTG-3Ј  LHRH-b  5Ј-GAC CAC CAC CCG GAC GGA GGC CAT AGC TCC AGT GTT GGC CTG GGC GCA GAC CGT AAG ACC AAT  GCT GAC CAC CTG-3Ј  LHRH-c  5Ј-TAT GCA GCA CTG GAG CTA CGG CCT GCG CCC GGG CCA ACA TTG GTC TTA TGG TCT CCG TCC AGG  TCA GCA CTG GTC CTA CGG CCT GCG GCC GGG CAG-3Ј  LHRH-d  5Ј-TAC TGC CCG GCC GCA GGC CGT AGG ACC AGT GCT GAC CTG GAC GGA GAC CAT AAG ACC AAT GTT  GGC CCG GGC GCA GGC CGT AGC TCC AGT GCT GCA- Table 1 ) were annealed and then inserted into the NdeI site of pET-thioredoxin-LHRH-4-D. This duplex encoded the LHRH trimer sequence. The resulting recombinant plasmid was named pET-thioredoxin-LHRH-7, which expressed recombinant thioredoxin with seven LHRH inserts and a C-terminal His-Tag sequence. The pET-thioredoxin-LHRH-7 was screened by digestion of corresponding restriction enzymes and expression of recombinant protein with the expected size. The recombinant protein thioredoxin-LHRH-7 (thioLHRH) (Fig. 1 ) was verified by Western blotting. It was collected and purified as described for ovalbumin-LHRH-7.
Bacterial Strain and Growth Conditions
The E. coli strain AD494(DE3) was used for cloning and expression of recombinant protein thioredoxin-LHRH-7. It was grown in tryptone-phosphate medium [13] containing 100 g/ml ampicillin. Protein expression was induced by adding iso-propyl-B-D-thio galactopyranoside to a final concentration of 1 mM when the culture reached an OD 600 of 0.5. Cultures were then incubated for an additional 3 h at 37ЊC. Thioredoxin-LHRH-7 was purified as described previously for ovalbumin-LHRH-7.
Animals and Treatments Experiment 1. All procedures performed on mice in this study were approved by the Washington State University Institutional Animal Care and Use Committee (protocol 1780). Forty-five male BALB/c mice (3 mo of age) were divided into four treatment groups of 10 mice each and one untreated control group of five mice. Each treated mouse was injected with 10 g of one of four proteins suspended in 100 l of Z-max adjuvant (Zonagen Inc., The Woodlands, TX), which is specifically designed for fusion proteins with a His-Tag. Proteins injected were thioredoxin-LHRH-7 (thioLHRH) and thioredoxin (thio) as a control or ovalbumin-LHRH-7 (ovaLHRH) and ovalbumin (ova) as a control. The primary immunization was followed with booster injections 30 and 60 days later. To indicate that the same protein was injected at each immunization, the treatments were written using the following format: thioLHRHthioLHRH-thioLHRH, thio-thio-thio, ova-ova-ova, and ovaLHRH-ovaLHRH-ovaLHRH. All proteins were administered intramuscularly on respective sides of the base of the tail for the primary immunization and the first booster and subcutaneously at the base of the neck for the second booster. Approximately 2 wk after the second booster, all mice were killed using CO 2 gas, and blood was collected via cardiac puncture for analysis of LHRH antibody production. The testes, epididymides, and vesicular glands (including the anterior portion of the prostate) were removed and weighed. Body weight for each mouse was also recorded.
Experiment 2. Ninety male BALB/c mice (3 mo of age) were divided into 10 treatment groups. Eight groups were injected subcutaneously with equimolar amounts of protein (0.4 nmol) suspended in 100 l of Immumax adjuvant (Zonagen), another adjuvant designed for His-Tag fusion proteins. All proteins were administered intramuscularly on respective sides of the base of the tail for the primary immunization and the first booster and were administered subcutaneously at the base of the neck for the second booster. Control treatments consisted of one group injected with an ova/thio-ova/thio-ova/thio cocktail, an untreated intact control group, and a surgically castrated positive-control group. Six treatment groups received either ovalbumin-LHRH-7 or thioredoxin-LHRH-7 given as a primary immunization, followed by two boosters given at 30-day intervals, with dif- OL ϭ ovalbumin-LHRH-7; TL ϭ thioredoxin-LHRH-7. * Ten micrograms of protein per injection. Pooled controls include untreated control (n ϭ 5), thioredoxin (n ϭ 10), and ovalbumin (n ϭ 10) treatments. a,b,c Treatments with the same superscripts are not significantly different (P Ͻ 0.05).
ferent combinations of either ovalbumin-LHRH-7 or thioredoxin-LHRH-7, as presented in Table 3 . The last treatment group received a cocktail (ovaLHRH/thioLHRHovaLHRH/thioLHRH-ovaLHRH/thioLHRH) containing 0.2 nmol of each protein given each immunization. Two weeks after the second booster, animals were killed, and data were collected as in experiment 1.
LHRH Antibody Titer Determination
For both experiments, percentage of 125 I-LHRH bound for each serum sample was quantified at 1:1000 dilutions with the 125 I-LHRH binding assay previously described [14] . Sheep anti-mouse globulin was used as the second antibody at 1:20 dilution.
Iodination of LHRH was performed using LHRH (2.5 g/25 l H 2 O) with 0.5 mCi (5 l) 125 I, 30 l of 0.5 M PBS (pH 7.5), and 10 l Chloramine-T (600 ng/10 l of 0.5 M PBS, pH 7.5). 125 I-LHRH was separated on a QAESephadex column using column buffer (10 mM Tris; 1 mM CaCl 2 ; 0.1% BSA, pH 7.2). The percentage of 125 I-LHRH bound to serum diluted 1:1000 was used as the index for LHRH antibody titers.
LHRH Affinity Assay
Serum samples from mice from both experiments (n ϭ 19) were analyzed for LHRH antibody affinity. Samples were chosen on the basis of three characteristics. Mice had 1) high titers and good biological response (decreased vesicular gland and anterior prostate weights), 2) low titers with good biological response, or 3) high titers but no biological response. Each serum sample was diluted in EDTA-PBS to attain 50% antibody binding as precisely as possible. Two hundred l of the diluted serum was then added to multiple tubes, and displacement with increasing quantities of unlabeled LHRH was performed. Approximately 47 000 dpm of 125 I-LHRH (specific activity, 100 Ci/g) was added to each tube along with unlabeled LHRH ranging from 0 to 91 nM. The displacement curves for each mouse were graphed, and the affinity was defined as the amount of unlabeled LHRH needed to displace 50% of the bound 125 I-LHRH. All samples for each experiment were analyzed in one assay.
Statistical Analyses
Data from both experiments were analyzed statistically by the Statistical Analysis System [15] . Analysis of variance was performed for a one-way treatment structure in a completely randomized design for all characteristics (testicular weight, epididymal weight, vesicular gland and anterior prostate weight, body weight, and LHRH antibody titer), and the differences among means were analyzed using Fisher's Least Significant Difference (LSD) test. Correlation among anti-LHRH titers and other characteristics was also analyzed [16] .
Because only nonstatistical differences were present between the three control groups in experiment 1, all controls were pooled into one control group for statistical analysis. Similarly, in experiment 2, there were no significant differences between the untreated control group and the control group receiving the ova/thio-ova/thio-ova/thio cocktail. Therefore, these groups were pooled and became the intactcontrols group.
It was determined that animals responded to the treatment or did not respond on the basis of vesicular gland and anterior prostate weight. To increase our confidence in determining the efficacy of treatments, only animals with vesicular gland and anterior prostate weight more than four standard deviations below the mean for the pooled controls were considered responsive to the treatment. Chi-square analysis was performed to determine whether the proportion of responsive mice was similar across treatments.
RESULTS
LHRH Antibody Titer and Biological Response
Experiment 1. The treatment means for LHRH antibody titer in both the ovaLHRH-ovaLHRH-ovaLHRH and the thioLHRH-thioLHRH-thioLHRH treatments were higher than the mean value for the pooled controls (P Ͻ 0.01). Mice treated with these two proteins also had lower (P Ͻ 0.05) vesicular gland/anterior prostate weight, testicular weight, and epididymal weight ( Table 2 ). The treatment means for both vesicular gland/anterior prostate weight and testicular weight for thioLHRH-thioLHRH-thioLHRH and ovaLHRH-ovaLHRH-ovaLHRH were not significantly different from each other when compared on an equal-weight administration of 10 g per immunization. Also, the two treatments were not significantly different on the basis of the percentage of responsive mice per treatment (40% for ovaLHRH-ovaLHRH-ovaLHRH and 60% for thioLHRHthioLHRH-thioLHRH; Fig. 2 ). Vesicular gland and anterior prostate weight was correlated (P Ͻ 0.0001) with antibody titers (r ϭ Ϫ0.64).
Although significant (P Ͻ 0.05), testicular weight was not as highly correlated with antibody titers (r ϭ Ϫ0.31) as was vesicular gland and anterior prostate weight. Nevertheless, testicular weight was highly correlated (P Ͻ 0.0001) with vesicular gland and anterior prostate weight (r ϭ 0.64). Epididymal weight was lower (P Ͻ 0.05) in the ovaLHRH-ovaLHRH-ovaLHRH treatment than in the thioLHRH-thioLHRH-thioLHRH treatment. Body weight was lower (P Ͻ 0.05) for the thioredoxin-LHRH-7 treatment animals compared with that of controls or the ova-LHRH-ovaLHRH-ovaLHRH group.
Experiment 2. Table 3 shows LHRH antibody titer, vesicular gland and anterior prostate weight, testicular weight, and body weight of mice immunized with LHRH fusion proteins. All treatments had higher LHRH antibody titers (P Ͻ 0.05) compared with the intact controls except for the ovaLHRH-thioLHRH-thioLHRH treatment, which was not significantly different from the intact control group (P Ͼ 0.05). Similarly, all treatments except the ovaLHRHthioLHRH-thioLHRH treatment also had lower vesicular gland and anterior prostate weight, testicular weight, and epididymal weight (P Ͻ 0.05). As expected, the castrate control animals did not produce any LHRH antibodies, but vesicular gland and anterior prostate weight was significantly lower than in the intact controls. The cocktail treatment had the lowest mean vesicular gland and anterior prostate weight at 52 Ϯ 24 mg compared to the intact controls at 259 Ϯ 8 mg.
The correlation between vesicular gland and anterior prostate weight and anti-LHRH titers for all treatments (excluding the castrate control group) was Ϫ0.53 (P Ͻ 0.0001). The percentage of animals in each treatment with decreased vesicular gland and anterior prostate weight (responsive animals) can be seen in Figure 3 . Biological responses ranged from 11% (ovaLHRH-ovaLHRH-thio-LHRH) to 89% (thioLHRH-thioLHRH-ovaLHRH). When compared on the basis of percentage of responsive animals in each treatment, all treatments were significantly different from the pooled intact controls except for the ovaLHRHthioLHRH-thioLHRH treatment, which was also not significantly different from the thioLHRH-thioLHRH-thio-LHRH or ovaLHRH-ovaLHRH-thioLHRH treatments.
Both testicular and epididymal weight were highly correlated (P Ͻ 0.0001) with LHRH antibody titers (r ϭ Ϫ0.48 and Ϫ0.53, respectively). All treatments were significantly lower in body weight compared with the intact controls.
LHRH Affinity
The amount of nonlabeled LHRH needed to displace 50% of the bound 125 I-LHRH ranged from approximately 0.009-9.1 nM for the animals evaluated. Examples of low-, medium-, and high-affinity samples are presented in Figure 4 .
DISCUSSION
In both experiments, immunization with ovalbumin-LHRH-7 or thioredoxin-LHRH-7, alone or in combination, successfully induced an immune response, as indicated by increased LHRH antibody titers. This immune response resulted in the production of antibodies against LHRH, which were biologically effective, as seen by decreases in vesicular gland and anterior prostate weight.
In experiment 1, only 80% of the thioLHRH-thioLHRHthioLHRH-and 50% of the ovaLHRH-ovaLHRH-ova-LHRH-treated animals had LHRH antibody titers above 50%. This resulted in 60% and 40%, respectively, of the treatment animals exhibiting a biological response. Although greater antibody response rates have been achieved by other researchers, a wide variation of responses is often seen in LHRH vaccines [3] . Although closely related mice of the same strain were used in this experiment, it is still possible that individual variation among mice accounted for some of the variation within treatment seen in this experi- ment. It is also possible that use of the same carrier for each injection (primary immunization and first and second booster injections) caused a carrier-induced immune suppression [17] .
To explore this hypothesis, in experiment 2, the two vaccines were alternated between primary immunization and first and second boosters, and both vaccines were also administered simultaneously (cocktail injection) to determine whether using more than one carrier would improve the immune response. In this experiment, antibody responses for each treatment (binding 50%) ranged from 67 to 100%, indicating that using two different carriers either simultaneously or in combination can in some instances improve the immune response compared with the case of injection of either ovalbumin-LHRH-7 or thioredoxin-LHRH-7 alone. Surprisingly, the cocktail injection was as effective as alternating the fusion proteins. This could be due to maintaining the same amount of LHRH per injection while decreasing by half the amount of each one of the carrier proteins. This would result in a higher proportion of LHRH in relation to each carrier protein.
The vast improvement in antibody response to ova-LHRH-ovaLHRH-ovaLHRH seen from the first experiment to the second (50-89%) is most likely due to the increased dosage (by twofold) given in the second experiment because proteins were administered on an equimolar basis and not by overall weight. This was done so that theoretically, an equal number of LHRH molecules would be given to each animal so that valid comparisons could be made between treatments.
Although LHRH antibody titers and vesicular gland and anterior prostate weight were strongly correlated in both experiments, a small number of animals had relatively high antibody binding and no biological response or had low binding with good biological response. Two possible explanations for this are individual differences in antibody affinity and timing of mouse death.
For immunoneutralization of a hormone to occur, antibodies must not only be present but also must have adequate affinity to tightly bind to the hormone. Analysis of antibody affinities from selected animals showed great variation among affinity values (Table 4) LHRH titers and good biological response had high antibody affinities, suggesting that the high affinity of the LHRH antibodies was able to overcome low antibody production. As a group, mice with high antibody binding and no biological response had low antibody affinity; however, two of these mice had antibodies with similar affinity to antibodies from mice that exhibited a good biological response. It is possible that the mice with high antibody binding, high affinity, and no biological response were late in developing an antibody response and that although antibody binding was high when they were killed, there was not sufficient time for the vesicular gland and anterior prostate to diminish in size before death.
Although epididymal and testicular weights were significantly lower than those in pooled controls for mice in all treatments except one, the correlation for these characteristics and antibody titers were lower than the correlation for vesicular gland and anterior prostate weight and antibody titer. This is primarily because on the basis of percentage of weight, the anterior prostate and vesicular glands diminish more drastically than the testes and epididymides, making differences from controls more detectable. This could be due to a higher proportion of cells in the anterior prostate and vesicular gland being androgen dependent, with proportionally fewer cells in the testis being LH dependent or cells in the epididymis being androgen dependent.
Despite these lower correlations, testicular weight was highly correlated (P Ͻ 0.001) with vesicular gland and anterior prostate weight (r ϭ 0.64 and 0.82 in experiments 1 and 2, respectively). Epididymal weight was also highly correlated (P Ͻ 0.001) with vesicular gland and anterior prostate weight in experiments 1 (r ϭ 0.64) and 2 (r ϭ 0.85). This suggests that animals that were responsive to the immunization (on the basis of vesicular gland and anterior prostate weight) also had diminished testes and epididymides. This would be expected if the LHRH in hypothalamic portal circulation was diminished or completely removed, resulting in decreased serum testosterone concentrations and atrophy of the accessory sex glands as well as in lower testicular and epididymal weights. Although serum testosterone concentrations were not measured in this study, accessory sex gland weight has often been used as a bioassay for determining relative testosterone concentrations.
In general, animals immunized with LHRH fusion proteins had body weight significantly lower than the intact control mice and similar to surgically castrated mice. Because of the anabolic effect that testosterone has on the body, diminished testosterone concentrations would result in slower weight gain.
Both of the fusion proteins used in this study, alone or in combination, induced the production of anti-LHRH antibodies and were effective in decreasing the size and weight of the vesicular gland and anterior prostate, testes, and epididymides. None of the treatments had 100% efficacy on the basis of diminished vesicular gland and anterior prostate weight. This problem of not reaching 100% effectiveness may be associated with individual animal variation or with some type of carrier-induced immune suppression. Some of the treatments using a combination of the two proteins did result in higher biological response rates, suggesting that the carrier does play a role in the response. Overall effectiveness could also be diminished if the antibodies produced do not have sufficient affinity to neutralize LHRH.
This study shows that both ovalbumin-LHRH-7 and thioredoxin-LHRH-7 can dramatically decrease the size and weight of the vesicular glands and the anterior portion of the prostate in mice through immunoneutralization of LHRH. This results in decreased LH concentrations, causing testosterone production by Leydig cells to decrease, resulting in atrophy of androgen-dependent organs such as the prostate. Because ovalbumin-LHRH-7 and thioredoxin-LHRH-7 are genetically engineered proteins, preparations of these vaccines should be highly homogeneous, which potentially could allow for FDA approval of these vaccines in humans and/or farm animals. Results from this study indicate that these proteins may be effective in treating androgen-dependent prostate carcinoma because of their ability to induce hypoplasia in the anterior prostate of mice.
